HCPCS G9210: Hepatitis C Quantitative RNA Test Not Performed (4-12 Weeks) - OpenPayer

Summary & Overview

HCPCS G9210: Hepatitis C Quantitative RNA Test Not Performed (4-12 Weeks)

HCPCS Level II code G9210 documents that a quantitative Hepatitis C virus (HCV) RNA test was not performed between 4 and 12 weeks after the start of antiviral therapy due to documented reasons (for example, treatment discontinuation during the testing window, medical reasons, or patient choice). This code is used as an exception indicator in clinical monitoring and quality measurement frameworks for HCV treatment, clarifying why a recommended virologic assessment was not completed. Nationally, accurate use of G9210 helps health systems and payers track adherence to HCV monitoring protocols while distinguishing appropriate exceptions from missed care.

Payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for on-treatment HCV RNA monitoring, how G9210 functions within quality reporting, and typical settings where the code is applied. The publication outlines common benchmarks and policy considerations influencing payer coverage and reporting, summarizes implications for outpatient clinics and laboratories, and identifies areas where documentation and coding affect quality measurement and claims reporting. Data not available in the input for payer-specific modifiers, associated taxonomies, ICD-10 diagnoses, related codes, or service-line details are noted as unavailable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9210HCPCS Level IIHepatitis CHCV RNA testingquality measurementlaboratory monitoringoutpatient careclinical documentation

Billing Code Overview

HCPCS Level II code G9210 indicates that quantitative Hepatitis C virus (HCV) RNA testing was not performed between 4 and 12 weeks after initiation of antiviral treatment for documented reason(s). Examples of documented reasons include patient treatment discontinuation during the testing period prior to testing, other medical reasons, patient declined, or other patient reasons. The code reflects a clinical quality measure exception rather than performance of a laboratory test.

Service type: Laboratory quality/clinical monitoring exception documentation

Typical site of service: Outpatient clinic or ambulatory care settings where HCV antiviral therapy is initiated and monitored, including infectious disease clinics, hepatology clinics, primary care practices managing HCV, and associated outpatient laboratory services.

Clinical & Coding Specifications

Clinical Context

A typical patient is a 55-year-old person with chronic hepatitis C virus (HCV) infection who began direct-acting antiviral (DAA) therapy. The clinic documents treatment initiation (baseline HCV RNA quantitative) and schedules follow-up HCV RNA testing at 4–12 weeks after treatment start to assess early virologic response. During the 4–12 week window the patient either discontinues therapy due to an adverse event, is hospitalized for an unrelated acute medical condition, declines the blood draw, or has another documented reason that prevents testing. The electronic health record contains a treatment start date, order for HCV quantitative RNA, and a clinician note documenting the reason testing was not performed. Billing staff assign HCPCS Level II code G9210 to indicate that the expected on‑treatment quantitative HCV RNA test between weeks 4 and 12 was not completed for a documented reason. Typical workflow steps include: order entry for HCV RNA at treatment initiation, scheduling of follow-up labs, documentation of discontinuation or patient refusal in the chart, and coding/billing using G9210 with accompanying visit codes or laboratory claims as appropriate.

Coding Specifications

Modifier	Description	When to Use
`25`	Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service

HCPCS G8924: Spirometry Results Documented (FEV1/FVC < 70%)

HCPCS-G0067-DENTISTRY-MIPS-SPECIALTY-SET

HCPCS G0067: Dentistry MIPS Specialty Set

HCPCS-G8953-ONCOLOGY-QUALITY-MEASURES-COMPLETED

HCPCS G8953: Completion of Oncology Quality Measures

HCPCS-G8585-ANTI-LIPID-TREATMENT-DISCHARGE

HCPCS G8585: Anti-lipid Treatment at Discharge

HCPCS-G9663-LDL-C-GE-190-MGDL

HCPCS G9663: LDL-C Result ≥ 190 mg/dL

HCPCS-G9088-COLON-CANCER-ADENOCARCINOMA-DISEASE-STATUS-M1-NO-EVIDENCE-OF-DISEASE

HCPCS G9088: Colon Cancer, Adenocarcinoma, Disease Status (m1, No Evidence of Disease)

HCPCS-G9593-PEDIATRIC-MINOR-HEAD-TRAUMA-PECARN-LOW-RISK

HCPCS G9593: Pediatric Minor Blunt Head Trauma, PECARN Low Risk

HCPCS-G9780-RHABDOMYOLYSIS-DIAGNOSIS-CAPTURE

HCPCS G9780: Rhabdomyolysis Diagnosis Capture

HCPCS-G1003-CLINICAL-DECISION-SUPPORT-APPROPRIATE-USE

HCPCS G1003: Clinical Decision Support Mechanism for Appropriate Use Criteria

HCPCS-G9412-CIED-INFECTION-DEVICE-REMOVAL-OR-REVISION

HCPCS G9412: CIED Infection Requiring Device Removal or Surgical Revision

Showing 1–10 of 1996

Taxonomy Code	Specialty	Notes
`207RP0014X`	Infectious Disease	Specialists who manage hepatitis C therapy and interpret HCV RNA monitoring.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`B18.2`	Chronic viral hepatitis C	Primary diagnosis for patients receiving antiviral therapy and requiring on-treatment HCV RNA monitoring.

Z79.899 | Other long term (current) drug therapy | May be used to indicate ongoing antiviral therapy management.

Z20.2 | Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission | May be present in exposure history; less commonly used as primary for monitoring but relevant in public health context.

R79.89 | Other specified abnormal findings of blood chemistry | May be used when laboratory abnormalities are documented during HCV treatment follow-up.

Z91.19 | Patient's other noncompliance with medical treatment and regimen | Used when a patient declines testing or otherwise fails to follow through with recommended laboratory monitoring.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`87436`	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C virus, direct probe technique (e.g., branched DNA), quantification	Common laboratory test used for baseline and on-treatment quantitative HCV RNA measurement; typically ordered at treatment initiation and at 4–12 weeks.

87520 | Infectious agent detection by nucleic acid (DNA or RNA), hepatitis C virus, amplified probe technique, quantitative | Alternative method for HCV RNA quantification; may be the ordered test that was not completed during the 4–12 week window.

80061 | Lipid panel | Routine laboratory monitoring that may occur alongside HCV management; often performed at baseline or during treatment visits.

36415 | Collection of venous blood by venipuncture | The specimen collection procedure that would be performed to obtain blood for HCV RNA testing; may be documented as not completed if patient refused or was unavailable.

99213 | Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes | Common E/M code used for follow-up visits where the clinician documents the reason the 4–12 week HCV RNA test was not performed.

OpenPayer